pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

33,606 catalysts · 18,786 approval · 4,871 device 510k · 3,957 grant · 2,000 device recall · 1,926 device pma · 1,066 recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
to 2026-03-31×clear all
type
  • approval18,786
  • device 510k4,871
  • grant3,957
  • device recall2,000
  • device pma1,926
  • recall1,066
  • device adverse event1,000
  • earnings7
  • therapy area

    no tagged catalysts yet

    Week of Dec 21, 2020

    8
    ›Dec 22, 2020approval2079d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: WATSON LABS INC. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗
    ›Dec 22, 2020approval2079d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: SIGMAPHARM LABS LLC. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗
    ›Dec 22, 2020approval2079d agoAMBRISENTAN — FDA approvalSigmapharm Laboratories LLC

    Sponsor: SUN PHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2020approval2079d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2020approval2079d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 23, 2020approval2078d agoACTIQ (FENTANYL CITRATE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: CEPHALON. Form: TROCHE/LOZENGE. Route: TRANSMUCOSAL

    full page →fda approvals ↗
    ›Dec 23, 2020approval2078d agoFENTORA (FENTANYL CITRATE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: CEPHALON. Form: TABLET. Route: BUCCAL, SUBLINGUAL

    full page →fda approvals ↗
    ›Dec 24, 2020approval2077d agoEPIPEN E Z PEN (EPINEPHRINE) — FDA approvaladrenaline

    Sponsor: VIATRIS. Form: INJECTABLE. Route: INTRAMUSCULAR

    full page →adrenaline →fda approvals ↗

    Week of Dec 28, 2020

    7
    ›Dec 28, 2020approval2073d agoLURASIDONE HYDROCHLORIDE — FDA approvalSumitomo Pharma America Inc

    Sponsor: CHARTWELL RX. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 29, 2020approval

    Week of Jan 4, 2021

    5
    ›Jan 6, 2021approval2064d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalFLUOXETINE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

    full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 6, 2021approval

    Week of Jan 11, 2021

    15
    ›Jan 11, 2021approval2059d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Jan 13, 2021

    Week of Jan 18, 2021

    9
    ›Jan 19, 2021approval2051d agoVERQUVO (VERICIGUAT) — FDA approvalMerck & Co., Inc.

    Sponsor: MSD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 20, 2021approval

    Week of Jan 25, 2021

    6
    ›Jan 25, 2021approval2045d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 25, 2021approval
    ← prev
    page 238 of 673
    next →
    2072d ago
    OPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Dec 29, 2020approval2072d agoMEN'S ROGAINE (MINOXIDIL) — FDA approvalVeradermics, Inc

    Sponsor: KENVUE BRANDS. Form: AEROSOL, FOAM. Route: TOPICAL

    full page →fda approvals ↗
    ›Dec 31, 2020approval2070d agoALEVE (NAPROXEN SODIUM) — FDA approvalNAPROXEN SODIUM

    Sponsor: BAYER. Form: TABLET. Route: ORAL

    full page →NAPROXEN SODIUM →fda approvals ↗
    ›Dec 31, 2020approval2070d agoALEVE (NAPROXEN SODIUM) — FDA approvalNAPROXEN SODIUM

    Sponsor: BAYER. Form: TABLET. Route: ORAL

    full page →NAPROXEN SODIUM →fda approvals ↗
    ›Dec 31, 2020approval2070d agoALEVE (NAPROXEN SODIUM) — FDA approvalNAPROXEN SODIUM

    Sponsor: BAYER. Form: TABLET. Route: ORAL

    full page →NAPROXEN SODIUM →fda approvals ↗
    ›Dec 31, 2020approval2070d agoALEVE (NAPROXEN SODIUM) — FDA approvalNAPROXEN SODIUM

    Sponsor: BAYER. Form: TABLET. Route: ORAL

    full page →NAPROXEN SODIUM →fda approvals ↗
    2064d ago
    OLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalFLUOXETINE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

    full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 6, 2021approval2064d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalFLUOXETINE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

    full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 6, 2021approval2064d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalFLUOXETINE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

    full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 6, 2021approval2064d agoQVAR REDIHALER (BECLOMETHASONE DIPROPIONATE) — FDA approvalSOLIGENIX, INC.

    Sponsor: NORTON WATERFORD. Form: AEROSOL, METERED. Route: INHALATION

    full page →fda approvals ↗
    approval
    2057d ago
    ZYPREXA RELPREVV (OLANZAPINE PAMOATE) — FDA approvalCHEPLAPHARM Arzneimittel GmbH

    Sponsor: CHEPLAPHARM. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 13, 2021approval2057d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jan 13, 2021approval2057d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jan 13, 2021approval2057d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 14, 2021approval2056d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoGIMOTI (METOCLOPRAMIDE HYDROCHLORIDE) — FDA approvalEvoke Pharma Inc

    Sponsor: QOL MEDCL. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Jan 14, 2021approval2056d agoVINCRISTINE SULFATE PFS (VINCRISTINE SULFATE) — FDA approvalVINCRISTINE SULFATE PFS

    Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

    full page →VINCRISTINE SULFATE PFS →fda approvals ↗
    ›Jan 15, 2021approval2055d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Jan 15, 2021approval2055d agoNOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approvalNOREPINEPHRINE BITARTRATE

    Sponsor: BAXTER HLTHCARE CORP. Form: SOLUTION. Route: INTRAVENOUS

    full page →NOREPINEPHRINE BITARTRATE →fda approvals ↗
    ›Jan 15, 2021approval2055d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    2050d ago
    VENOFER (IRON SUCROSE) — FDA approvalInternational Medication Systems Ltd

    Sponsor: AM REGENT. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 21, 2021approval2049d agoCABENUVA KIT (CABOTEGRAVIR) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2021approval2048d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Jan 22, 2021approval2048d agoSILIQ (BRODALUMAB) — FDA approvalBausch Health US LLC

    Sponsor: VALEANT LUXEMBOURG. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jan 22, 2021approval2048d agoLORBRENA (LORLATINIB) — FDA approvallorlatinib

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →lorlatinib →fda approvals ↗
    ›Jan 22, 2021approval2048d agoURSODIOL — FDA approvalURSODIOL

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →URSODIOL →fda approvals ↗
    ›Jan 22, 2021approval2048d agoCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

    Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL

    full page →cabozantinib s-malate →fda approvals ↗
    ›Jan 22, 2021approval2048d agoLUPKYNIS (VOCLOSPORIN) — FDA approvalvoclosporin

    Sponsor: AURINIA. Form: CAPSULE. Route: ORAL

    full page →voclosporin →fda approvals ↗
    2045d ago
    VFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 25, 2021approval2045d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 25, 2021approval2045d agoOLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalMicro Labs Ltd

    Sponsor: UMEDICA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 25, 2021approval2045d agoOLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Jan 26, 2021approval2044d agoVIGABATRIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    $ABBV256.42+0.37%
    $ABBV256.42+0.37%
    $MRK147.91-0.30%
    $VTRS16.51+1.04%
    $MANE98.41+0.49%
    $BMY66.81+0.35%
    $PFE28.46+1.79%
    $AUPH16.11-1.10%
    $AMRX17.54-2.61%
    $AMRX17.54-2.61%
    $BMY66.81+0.35%
    $SNGX
    $EXEL54.64+0.35%